Ashfield Meetings & Events makes two appointments
January 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Meetings, ashfield, events, ian anderson, jo brook
Healthcare event management firm Ashfield Meetings & Events has appointed Jo Brook as an engagement director and Ian Anderson joins …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Sandoz earns historic first FDA biosimilar vote
January 8, 2015Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio
Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
NHS searches for healthcare innovators
January 8, 2015Medical Communications, Sales and Marketing NHS, UK, innovation, programme, sir bruce keogh
NHS England and medical director Sir Bruce Keogh have launched an NHS Innovation Accelerator Programme. The initiative will invite healthcare …
Lilly appoints head of business development
January 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing darren carroll, lilly
Eli Lilly has promoted Darren Carroll to senior vice president of its corporate business development unit. Carroll has fulfilled the …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
Gilead acquires Phenex liver disease drugs
January 7, 2015Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex
Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …
Amgen and Novartis start cancer immunotherapy push
January 7, 2015Research and Development, Sales and Marketing Amgen, Caribou Biosciences, Intellia Therapeutics, Novartis, kite pharma
Amgen and Novartis have launched new licensing agreements with biotech companies that they hope will lead to the development of …
Liberation Unlimited promotes Danielle Guildford-Sharp
January 7, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Creston, Danielle Guildford-Sharp, health unlimited, liberation unlimited
UK marketing and communications agency Liberation Unlimited has promoted Danielle Guildford-Sharp to the role of account manager. Since joining Liberation …
Director General of EFPIA: “Pan-European HTA necessary”
January 6, 2015London, January 5 2015: Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Pfizer buys vaccine developer Redvax
January 6, 2015Research and Development, Sales and Marketing Pfizer, Vaccine, cmv, herpes, redbiotec, redvax, virus
Adding to its latest string of deals Pfizer has acquired vaccine developer Redvax – the pre-clinical arm of Swiss company …
BMS launches new fibrosis research collaboration
January 6, 2015Research and Development, Sales and Marketing BMS, BMS-986020, calibr, california, fibrosis, fibrotic
Bristol-Myers Squibb is entering into an agreement with the California Institute for Biomedical Research to develop new treatments for fibrotic …
Valeant recalls drug used on hospitalised infants
January 6, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, FDA, Valeant, manufacturing, recall, ribavirin, virazole
North American drug firm Valeant Pharmaceuticals has issued a voluntary nationwide recall of Virazole due to microbial contamination. Virazole (ribavirin …
UK nurse with Ebola in ‘critical condition’
January 6, 2015Research and Development, Sales and Marketing Africa, Ebola, GSK, Mapp, WHO, cafferky, johnson, zmapp
A British nurse that was diagnosed with Ebola last week is said to be in a critical condition at the …
MRC head joins CPRD as director
January 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, MRC, cprd, janet valentine
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced an appointment of a new director for The Clinical Practice …
Next-generation Cempra antibiotic meets endpoints
January 5, 2015Research and Development, Sales and Marketing Antibiotics, FDA, cempra, moxifloxacin, solitaire-oral
Cempra Pharmaceuticals has become the first company to publish results from a Phase III study completed under FDA regulations governing …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
